In yesterday’s Wall Street session, Organon & Co. (NYSE:OGN) shares traded at $23.61, up 1.94% from the previous session.
8 analysts cover Organon & Co. (NYSE:OGN), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $43.00 and a low of $23.00, we find $27.00. Given the previous closing price of $23.16, this indicates a potential upside of 16.58 percent. OGN stock price is now 13.33% away from the 50-day moving average and -2.84% away from the 200-day moving average. The market capitalization of the company currently stands at $6.02B.
The stock has received a hold rating from 4 analysts and a buy rating from 3. Brokers who have rated the stock have averaged $30.00 as their price target over the next twelve months.
With the price target of $33, Raymond James recently initiated with Outperform rating for Organon & Co. (NYSE: OGN).
Insiders disposed of 79,291 shares of company stock worth roughly $1.87 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in OGN stock. A new stake in Organon & Co. shares was purchased by BRANDYWINE GLOBAL INVESTMENT MANAGEMENT, LLC during the first quarter worth $21,015,000. GILMAN HILL ASSET MANAGEMENT, LLC invested $8,952,000 in shares of OGN during the first quarter. In the first quarter, MAGNETAR FINANCIAL LLC acquired a new stake in Organon & Co. valued at approximately $6,631,000. MARSHALL WACE, LLP acquired a new stake in OGN for approximately $2,796,000. U.S. CAPITAL WEALTH ADVISORS, LLC purchased a new stake in OGN valued at around $2,731,000 in the second quarter. In total, there are 1,031 active investors with 78.60% ownership of the company’s stock.
On Thursday morning Organon & Co. (NYSE: OGN) stock kicked off with the opening price of $23.34. During the past 12 months, Organon & Co. has had a low of $18.87 and a high of $32.43. The fifty day moving average price for OGN is $20.92 and a two-hundred day moving average price translates $24.30 for the stock.
The latest earnings results from Organon & Co. (NYSE: OGN) was released for Mar, 2023. According to the Drug Manufacturers – General Company, earnings per share came in at $1.31, beating analysts’ expectations of $1.01 by 0.3. This compares to $0.92 EPS in the same period last year. The net profit margin was 12.10% and return on equity was -77.90% for OGN. The company reported revenue of $1.61 billion for the quarter, compared to $1.58 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 1.45 percent. For the current quarter, analysts expect OGN to generate $1.58B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 06/15/2023. Investors who held shares on 05/15/2023 were paid a $0.28 dividend. On an annualized basis, this represents a $1.12 dividend and a 4.74% percent yield. There was an ex-dividend date of 05/12/2023 for this dividend. In terms of dividend payout ratio, OGN is presently at 38.20%.
Organon & Co.(OGN) Company Profile
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company’s biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
